Semax

What it is

Semax is summarized here from the public peptide research file, in this site's own wording. Synthetic peptide based on a fragment of the hormone ACTH. The material sold on this site is a research vial, not a branded finished drug, and it is not for human or veterinary use.

Regulatory status

Not FDA-approved, sold in the wellness/gray market, and approved in Russia. No. Semax is not approved by the FDA. As neutral regulatory facts: it is approved in Russia for stroke and cognitive indications; and in July 2026 the FDA's Pharmacy Compounding Advisory Committee gave semax a non-binding favorable advisory vote toward allowing it to be compounded under 503A, while FDA staff opposed it citing insufficient evidence. An advisory vote is only a recommendation; it does not make semax approved, and FDA rulemaking would still be required.

What the research shows

The headline finding recorded for it: Human evidence limited to small, mostly Russian studies; a 2026 FDA advisory vote was favorable but non-binding. Small Methodologically weak Single-country Often developer-affiliated, with little independent replication Semax is a synthetic seven-amino acid peptide based on a fragment of ACTH (adrenocorticotropic hormone), with added amino acids for stability. It was developed by Russian research institutes and is approved in Russia for stroke and cognitive and neurological conditions. Outside Russia it is discussed in wellness write-ups and research-supply channels for cognition and neuroprotection, and it is not an approved medicine in the United States. Semax is proposed to act as a nootropic and neuroprotectant by increasing levels of nerve-growth signals such as BDNF and NGF and modulating brain chemical systems. These effects are reported mainly in animal and laboratory studies. This describes the proposed mechanism, separate from demonstrated benefit in people. Both mechanism descriptions come mainly from animal and laboratory work, and neither has been shown to produce a benefit in people. Neither peptide is FDA-approved. An advisory vote is only a recommendation, and it does not make semax approved. The human evidence for both is limited in the same way: small, mostly Russian studies, often run by the developing institutions and not independently replicated. An analytical review notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish that either one works or that one works better than the other. Mechanistic and.

Evidence limits

Evidence label in the source library: Low research. This page does not give a dose, a route, or a schedule. It is not medical advice and it is not instructions for the research vials on this site.

Reported actions

• Human evidence limited to small, mostly Russian studies; a 2026 FDA advisory vote was favorable but non-binding